Archive restoration — 26 September 2026: This article has been restored from our original source files. Its publication date and reporting context remain unchanged; it is not a new update on current policy, availability or clinical guidance.
A plant-derived form of dronabinol has entered the UK pharmaceutical supply chain, creating a new option for unlicensed oral medicines made for individual patients. The development is technically important. It is not a new licensed cannabis medicine, a new clinical indication or a sudden expansion of NHS access.
Dunbar Pharmaceuticals announced on 18 August that its plant-derived dronabinol active pharmaceutical ingredient, sold under the name WaterClear THC, is now available in the UK through IPS Pharma. The companies say IPS intends to offer it in 5 mg and 10 mg capsules, a 25 mg/mL oral spray and 25 mg/mL oil drops through the UK “specials” pathway.[1]
That language needs unpacking.
Dronabinol is delta-9-tetrahydrocannabinol—the cannabinoid more commonly shortened to THC—prepared as a defined pharmaceutical ingredient. An active pharmaceutical ingredient, or API, is the component intended to produce the medicine’s effect. It is not, on its own, the finished product that a patient receives.
The announcement therefore concerns the start of a supply route: a standardised ingredient entering formulations prepared and supplied under existing UK controls. Whether that becomes meaningful for patients will depend on quality, prescribing decisions, evidence, consistency, price and reliable availability.
Why plant-derived dronabinol is noteworthy
Dronabinol is a molecule, not a brand and not a whole-plant extract. It can be manufactured synthetically or isolated from cannabis. When the final molecule is properly characterised, its origin does not automatically make one version clinically superior to another.
The plant-derived route may nevertheless matter to manufacturers and prescribers. It can offer an additional source of a known cannabinoid for precisely dosed formulations. Some patients and clinicians may prefer a plant-derived ingredient, while procurement teams may value another qualified supplier in a market where continuity has often been a problem.
The companies describe the API as produced under European good-manufacturing-practice oversight in Ireland.[1] An independent pharmaceutical trade report also described the UK launch and the planned formulation range.[2] These are useful facts about the commercial arrangement, but quality claims should ultimately be judged through regulatory documentation, testing and the conduct of the authorised manufacturer—not the tone of a launch announcement.
The relevant promise is consistency. A standardised API can be measured into a defined capsule or liquid strength, making dose changes easier to describe than with a product whose composition varies. That may help clinicians titrate cautiously and identify the balance between symptom relief and THC-related adverse effects.
Consistency is valuable. It does not establish efficacy for a particular condition.
What the UK specials pathway means
A “special” is an unlicensed medicine supplied to meet the particular clinical needs of an individual patient when an appropriate licensed product is not available.
The Medicines and Healthcare products Regulatory Agency makes clear that specials sit within a controlled supply chain. They may be manufactured, imported or distributed only through authorised routes and should not be supplied as if they were ordinary mass-market medicines.[3]
“Unlicensed” can sound like “unregulated”, but the terms are not interchangeable. A specials manufacturer must meet manufacturing and quality obligations. The product, however, has not gone through the standard marketing-authorisation process in which a regulator assesses a full package of evidence for a defined indication, dose, population and formulation.
That changes the distribution of responsibility. The prescriber must be satisfied that an unlicensed product is appropriate for the individual patient. The manufacturer must make it to an acceptable quality. The pharmacist must procure and supply it through the correct route. Claims cannot run ahead of the evidence simply because a product can legally be made.
The MHRA has also explained that organisations manufacturing cannabis-based products or handling cannabinoid APIs may require both medicines authorisations and Home Office controlled-drug permissions.[4] The regulatory framework surrounds the ingredient and the finished product; a new API does not bypass it.
What has actually changed
The practical change is that a UK specials manufacturer now has access to another source of plant-derived dronabinol and plans several oral dose forms.
Capsules can offer a fixed dose and familiar administration. Drops may permit smaller adjustments. An oral spray can provide another measured format. Having several presentations could help a specialist match the formulation to swallowing ability, titration needs and daily routine.
Those are formulation advantages, not proof of better outcomes.
Oral THC also behaves differently from inhaled cannabis. Its effects take longer to begin, can last longer and may be less predictable between individuals because absorption and liver metabolism vary. A person should not transfer a dose from an inhaled product to an oral one without clinical guidance.
The launch may also improve supply resilience. Medical-cannabis patients have repeatedly encountered product discontinuations, stock changes and substitutions. Another qualified API source gives manufacturers more options, although one announcement cannot prove long-term availability.
The most responsible measure of success will be mundane: prescriptions filled accurately, batches remaining consistent, shortages becoming less frequent and patients receiving clear instructions.
What has not changed
No new licensed indication was announced. The API’s availability does not demonstrate that dronabinol treats chronic pain, anxiety, sleep disturbance, post-traumatic stress disorder or any other condition.
It also does not mean that any doctor can casually prescribe it. UK access to most cannabis-based medicinal products remains specialist-led, and NHS guidance says only a small number of people are likely to receive an NHS prescription.[5]
The development does not automatically change:
- national clinical guidelines;
- the evidential threshold used by NHS services;
- which patients are suitable for THC;
- driving and impairment law;
- the need to consider interactions with other medicines;
- the difference between a specials product and a licensed medicine;
- the price ultimately paid by a private patient.
Commercial availability is therefore a necessary step in access, not a substitute for clinical evidence or public commissioning.
Why dose and format deserve attention
THC can produce dizziness, drowsiness, changes in attention, anxiety, altered perception and impaired coordination. The chance and severity of those effects vary with dose, route, previous exposure and the individual patient.
Precisely labelled oral formulations may support a “start low, go slow” approach, but the phrase should not become a reassurance slogan. Titration requires a goal and a stop point. A clinician should know what improvement is being sought, which adverse effects are unacceptable and when treatment will be reviewed.
Patients also need explicit advice about driving. A legal prescription is not evidence that someone is fit to drive while impaired. The presence of a measured dose does not make THC’s effects irrelevant.
Storage matters too. Concentrated oral THC should be kept in its original labelled packaging and away from children and anyone for whom it was not prescribed. Oils and sprays can look less conspicuous than dried flower, which makes clear household precautions more—not less—important.
The evidence gap remains
One advantage of a defined API is that it can support more reproducible research. Trials are easier to interpret when investigators know the dose and composition participants receive.
That opportunity should now be used.
Manufacturers and clinics can collect useful real-world safety information, but observational reports should not be dressed up as controlled evidence. Product-specific trials are needed to establish whether a particular dronabinol formulation improves a defined outcome, at what dose and with which harms.
The UK also needs better transparency around unlicensed prescribing. Aggregate information about indications, dose ranges, discontinuation, adverse events and patient-reported outcomes could improve care without exposing individual records.
If plant-derived dronabinol becomes more widely used, the public-interest question is not whether it is “natural”. It is whether it is consistent, appropriately prescribed, monitored and supported by evidence.
What patients should ask
Someone offered an unlicensed dronabinol formulation should receive answers to practical questions:
- Why is this being recommended instead of a licensed treatment?
- What symptom or functional goal are we trying to improve?
- What is the starting dose, and how slowly will it change?
- When should I expect an effect from this oral formulation?
- Which side effects mean I should reduce the dose or seek advice?
- Could it interact with my other medicines or alcohol?
- What are the driving and workplace implications?
- When will the treatment be reviewed, and what would make us stop?
- What will it cost if the dose increases?
A careful prescription is a shared plan, not just a product name.
The editorial view
The UK medical-cannabis sector needs more pharmaceutical discipline, not less. A well-characterised plant-derived dronabinol ingredient, supplied through an authorised manufacturer in measured oral formats, fits that direction.
It offers grounds for measured optimism: more formulation choice, the possibility of better supply resilience and a platform for cleaner product-specific evidence. It may be particularly useful where a clinician wants THC without the variability or administration issues associated with inhaled flower.
But the industry weakens its case when a supply-chain development is presented as a clinical breakthrough. This launch does not make dronabinol a licensed treatment for a new condition, remove the risks of THC or solve the unequal access faced by UK patients.
The next step is not louder promotion. It is dependable supply, transparent quality information, responsible prescribing and research that connects the formulation to outcomes patients can actually feel in daily life.
That is how a new ingredient becomes useful medicine.
Key takeaways
- A plant-derived dronabinol API is now being supplied in the UK through IPS Pharma, according to an 18 August company announcement.
- Planned specials formulations include 5 mg and 10 mg capsules, a 25 mg/mL oral spray and 25 mg/mL oil drops.
- An API is the active ingredient, not the finished medicine a patient receives.
- UK specials are unlicensed medicines made or supplied for an individual patient’s clinical need through authorised routes.
- The launch adds a supply and formulation option; it is not a new marketing authorisation, clinical indication or NHS-access policy.
- Oral THC requires careful titration because onset, duration, impairment and adverse effects vary between people.
- Patients should receive clear advice on goals, dose, interactions, driving, storage, review and cost.
- The real test will be consistent quality, reliable supply and product-specific evidence—not whether the THC began in a plant.
Sources
- Dunbar Pharma Brings Plant-Derived Dronabinol API to the UK Market — Business Wire
- Irish Manufacturer Brings EU-GMP-Certified Dronabinol API to the UK — Manufacturing Chemist
- Supply Unlicensed Medicinal Products (Specials) — MHRA
- MHRA Process for Cannabis-Based Product Manufacturing and API Registration — MHRA Inspectorate
- Medical Cannabis — NHS
